Frank Stegelmann

5PUBLICATIONS
26CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Gene and molecular therapyNanotoxicology, health and safety
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jan 12, 2026
Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Andreas Burchert, Franck E Nicolini, Philipp le Coutre

|Feb 25, 2025
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN).

Kirsi Manz, Florian H Heidel, Steffen Koschmieder

|Feb 24, 2023
Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN).

Frank Stegelmann, Lino L Teichmann, Florian H Heidel

|Nov 17, 2021
Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN.

Frank Stegelmann, Kai Wille, Hannah Busen

|Jul 04, 2020
Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN.

Frank Stegelmann, Kai Wille, Hannah Busen

Pageof 1

Frequent Collaborators

2 joint publications

Hannah Busen

2 joint publications

Christiane Fuchs

2 joint publications

Thomas Ernst

2 joint publications

Konstanze Döhner